Clinical Trial Update: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating almonertinib in combination with chemotherapy as first-line therapy for EGFR mutation with concomitant tumor suppressor gene alteration…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN